Side effects of deferasirox iron chelation in patients with beta thalassemia major or intermedia

Murtadha Al-Khabori, Sunil Bhandari, Mohammed Al-Huneini, Khalil Al-Farsi, Vinodh Panjwani, Shahina Daar

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Objectives: Chelating agents remain the mainstay in reducing the iron burden and extending patient survival in homozygous betathalassemia but adverse and toxic effects may increase with the institution and long term use of this essential therapy. This study aimed to estimate the incidence of deferasirox (DFX) side effects in patients with thalassemia major or intermedia. Methods: A retrospective study of 72 patients (mean age: 20.3±0.9 yrs; 36 male, 36 female) with thalassemia major or intermedia treated at Sultan Qaboos University Hospital, Oman, was performed to assess the incidence of side effects related to deferasirox over a mean of 16.7 month follow-up period. Results: Six patients experienced rashes and 6 had gastro-intestinal upset. DFX was discontinued in 18 patients for the following reasons: persistent progressive rise(s) in serum creatinine (7 patients; 40% mean serum creatinine rise from baseline), feeling unwell (2), severe diarrhea (1), pregnancy (1), death unrelated to chelator (2) and rise in serum transaminases (2). Three patients were reverted to desferoxamine and deferiprone combination therapy as DFX was no longer biochemically effective after 18 months of therapy. There was no correlation between baseline serum ferritin and serum creatinine or a rise in serum creatinine. Cardiac MRI T2* did not change with DFX therapy. However, there was an improvement in liver MRI T2* (p=0.013). Conclusion: Renal side effects related to deferasirox appear to be higher than those reported in published clinical trials. Further larger studies are required to confirm these findings.

Original languageEnglish
Pages (from-to)121-124
Number of pages4
JournalOman Medical Journal
Volume28
Issue number2
DOIs
Publication statusPublished - 2013

Fingerprint

beta-Thalassemia
Iron
Creatinine
Serum
Chelating Agents
Oman
Poisons
Incidence
Therapeutics
Ferritins
Transaminases
deferasirox
Exanthema
Diarrhea
Emotions
Retrospective Studies
Clinical Trials
Kidney
Pregnancy
Survival

Keywords

  • Chelator
  • Kidney function
  • Thalassemia
  • Toxicity

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Side effects of deferasirox iron chelation in patients with beta thalassemia major or intermedia. / Al-Khabori, Murtadha; Bhandari, Sunil; Al-Huneini, Mohammed; Al-Farsi, Khalil; Panjwani, Vinodh; Daar, Shahina.

In: Oman Medical Journal, Vol. 28, No. 2, 2013, p. 121-124.

Research output: Contribution to journalArticle

Al-Khabori, Murtadha ; Bhandari, Sunil ; Al-Huneini, Mohammed ; Al-Farsi, Khalil ; Panjwani, Vinodh ; Daar, Shahina. / Side effects of deferasirox iron chelation in patients with beta thalassemia major or intermedia. In: Oman Medical Journal. 2013 ; Vol. 28, No. 2. pp. 121-124.
@article{7507c543dadd41169483d99d70e24a2e,
title = "Side effects of deferasirox iron chelation in patients with beta thalassemia major or intermedia",
abstract = "Objectives: Chelating agents remain the mainstay in reducing the iron burden and extending patient survival in homozygous betathalassemia but adverse and toxic effects may increase with the institution and long term use of this essential therapy. This study aimed to estimate the incidence of deferasirox (DFX) side effects in patients with thalassemia major or intermedia. Methods: A retrospective study of 72 patients (mean age: 20.3±0.9 yrs; 36 male, 36 female) with thalassemia major or intermedia treated at Sultan Qaboos University Hospital, Oman, was performed to assess the incidence of side effects related to deferasirox over a mean of 16.7 month follow-up period. Results: Six patients experienced rashes and 6 had gastro-intestinal upset. DFX was discontinued in 18 patients for the following reasons: persistent progressive rise(s) in serum creatinine (7 patients; 40{\%} mean serum creatinine rise from baseline), feeling unwell (2), severe diarrhea (1), pregnancy (1), death unrelated to chelator (2) and rise in serum transaminases (2). Three patients were reverted to desferoxamine and deferiprone combination therapy as DFX was no longer biochemically effective after 18 months of therapy. There was no correlation between baseline serum ferritin and serum creatinine or a rise in serum creatinine. Cardiac MRI T2* did not change with DFX therapy. However, there was an improvement in liver MRI T2* (p=0.013). Conclusion: Renal side effects related to deferasirox appear to be higher than those reported in published clinical trials. Further larger studies are required to confirm these findings.",
keywords = "Chelator, Kidney function, Thalassemia, Toxicity",
author = "Murtadha Al-Khabori and Sunil Bhandari and Mohammed Al-Huneini and Khalil Al-Farsi and Vinodh Panjwani and Shahina Daar",
year = "2013",
doi = "10.5001/omj.2013.31",
language = "English",
volume = "28",
pages = "121--124",
journal = "Oman Medical Journal",
issn = "1999-768X",
publisher = "Oman Medical Specialty Board",
number = "2",

}

TY - JOUR

T1 - Side effects of deferasirox iron chelation in patients with beta thalassemia major or intermedia

AU - Al-Khabori, Murtadha

AU - Bhandari, Sunil

AU - Al-Huneini, Mohammed

AU - Al-Farsi, Khalil

AU - Panjwani, Vinodh

AU - Daar, Shahina

PY - 2013

Y1 - 2013

N2 - Objectives: Chelating agents remain the mainstay in reducing the iron burden and extending patient survival in homozygous betathalassemia but adverse and toxic effects may increase with the institution and long term use of this essential therapy. This study aimed to estimate the incidence of deferasirox (DFX) side effects in patients with thalassemia major or intermedia. Methods: A retrospective study of 72 patients (mean age: 20.3±0.9 yrs; 36 male, 36 female) with thalassemia major or intermedia treated at Sultan Qaboos University Hospital, Oman, was performed to assess the incidence of side effects related to deferasirox over a mean of 16.7 month follow-up period. Results: Six patients experienced rashes and 6 had gastro-intestinal upset. DFX was discontinued in 18 patients for the following reasons: persistent progressive rise(s) in serum creatinine (7 patients; 40% mean serum creatinine rise from baseline), feeling unwell (2), severe diarrhea (1), pregnancy (1), death unrelated to chelator (2) and rise in serum transaminases (2). Three patients were reverted to desferoxamine and deferiprone combination therapy as DFX was no longer biochemically effective after 18 months of therapy. There was no correlation between baseline serum ferritin and serum creatinine or a rise in serum creatinine. Cardiac MRI T2* did not change with DFX therapy. However, there was an improvement in liver MRI T2* (p=0.013). Conclusion: Renal side effects related to deferasirox appear to be higher than those reported in published clinical trials. Further larger studies are required to confirm these findings.

AB - Objectives: Chelating agents remain the mainstay in reducing the iron burden and extending patient survival in homozygous betathalassemia but adverse and toxic effects may increase with the institution and long term use of this essential therapy. This study aimed to estimate the incidence of deferasirox (DFX) side effects in patients with thalassemia major or intermedia. Methods: A retrospective study of 72 patients (mean age: 20.3±0.9 yrs; 36 male, 36 female) with thalassemia major or intermedia treated at Sultan Qaboos University Hospital, Oman, was performed to assess the incidence of side effects related to deferasirox over a mean of 16.7 month follow-up period. Results: Six patients experienced rashes and 6 had gastro-intestinal upset. DFX was discontinued in 18 patients for the following reasons: persistent progressive rise(s) in serum creatinine (7 patients; 40% mean serum creatinine rise from baseline), feeling unwell (2), severe diarrhea (1), pregnancy (1), death unrelated to chelator (2) and rise in serum transaminases (2). Three patients were reverted to desferoxamine and deferiprone combination therapy as DFX was no longer biochemically effective after 18 months of therapy. There was no correlation between baseline serum ferritin and serum creatinine or a rise in serum creatinine. Cardiac MRI T2* did not change with DFX therapy. However, there was an improvement in liver MRI T2* (p=0.013). Conclusion: Renal side effects related to deferasirox appear to be higher than those reported in published clinical trials. Further larger studies are required to confirm these findings.

KW - Chelator

KW - Kidney function

KW - Thalassemia

KW - Toxicity

UR - http://www.scopus.com/inward/record.url?scp=84875916077&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875916077&partnerID=8YFLogxK

U2 - 10.5001/omj.2013.31

DO - 10.5001/omj.2013.31

M3 - Article

C2 - 23599881

AN - SCOPUS:84875916077

VL - 28

SP - 121

EP - 124

JO - Oman Medical Journal

JF - Oman Medical Journal

SN - 1999-768X

IS - 2

ER -